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Abstract 
Adriamycin-loaded albumin-heparin conjugate microspheres ~~R-~C~S) were evaluated as possible in- 
traperitoneal (i.p.) delivery systems for site-specific cytotoxic action. The biocompatibility of the microspheres after 
intraperitoneal injection was tested first. 1 day after i.p. administration of empty as well as drug-loaded AHCMS to 
male Balb/c mice, only a moderate increase in i.p. neutrophils was measured. 3 days after injection neutrophil levels 
were comparable with the controls. No significant increases in the numbers of other cell types were observed, 
indicating an acute inflammatory response which can be considered to be mild. Antitumour efficacy was tested in an 
L1210 tumour-bearing mouse model and in a CC531 tumour-bearing rat model. The use of ADR-AHCMS leads to 
longer survival times of mice and improved tumour growth deIay in rats, as compared with untreated controls and 
free drug treated animals. In both animal models higher adriamycin doses were initially tolerated if the drug was 
formulated in microspheres, although long-term adriamycin toxicity effects were evident in all treated groups. Doses 
and dosage schedules may be optimized to further reduce the toxic effects of the drug. 
Key words: Adriamycin; Microsphere; Biocompatibili~; Intra~eritoneal chemotherapy; Controlled release; Drug 
targeting 
1. Introduction 
is 
In certain applications regional chemotherapy 
established for elevating the therapeutic in- 
dices of conventional anticancer drugs. In the 
case of intracavitary malignancies, like brain tu- 
mours and regionalized abdomina1 pelvic or me- 
diastinal cancer, intracavitary administration of 
* Corresponding author: Tel: +31 53 89 29 68; Fax: + 31 53 
33 01 45. 
therapeutic agents allows higher drug levels at 
the site of the tumour than could be achieved 
with systemic chemotherapy (Knapp et al., 1983). 
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In the treatment of brain tumours the blood 
brain barrier is by-passed if the drugs are admin- 
istered intracranially. Intracranial administration 
of drugs by means of refillable silicon devices 
(Ueno et al., 1982) or by using chronically im- 
planted catheters (Bouvier et al., 1987) to treat 
brain tumours has been reported. Biodegradable 
polyanhydride discs loaded with bis(2-chloro- 
ethyl)-1-nitrosurea (BCNU), implanted intracra- 
nially after surgical resection of the primary tu- 
mour, appear to be more effective than standard 
intravenous treatments (Brem, 1990; Langer, 
1991). Another example of intracavitary chemo- 
therapy is the intrapleural administration of cy- 
tarabine in the treatment of malignant pleural 
effusions (Markman and Howell, 1987). 
Intraperitoneal (i.p.1 chemotherapy for the 
treatment of malignant diseases that remain 
largely confined there (e.g., ovarian carcinoma) 
has also been widely investigated. In the clinical 
situation prolonged infusions of drugs have been 
used. Using a dialysis catheter, high intracavitary 
concentrations of drug can be achieved and large 
volumes of fluid can be instilled, permitting treat- 
ment of all peritoneal surfaces (Knapp et al., 
1983; Regelson, 1986). The results have been 
promising though not spectacular, since most 
drugs are transferred rapidly out of the peri- 
toneal cavity (Wahl et al., 1988). Upon entering 
the systemic irculation via either the portal route 
or the lymphatic route, systemic toxicity is in- 
evitable. Markman and Howell (19871, however, 
mention that i.p. cytarabine, which mainly exits 
the peritoneal cavity via the portal circulation, is 
inactivated in the liver before entering the sys- 
temic circulation. Another approach is the co-ad- 
ministration of neutralizing agents via the intra- 
venous route to neutralize the drug transferred 
from the peritoneal cavity into the bloodstream. 
Systemic toxicity of i.p. cisplatin, for instance, can 
be neutralized by systemic thiosulphate (Howell 
et al., 1982). 
An alternative approach in i.p. chemotherapy 
has been the use of implantable drug delivery 
systems, designed for retention within the peri- 
toneal cavity following administration there. Upon 
intracavitary implantation the drug can be re- 
leased over an appropriate period. Heller et al. 
(1991) developed bioerodible, 5-FU-loaded poly 
(ortho ester) devices which, after i.p. implanta- 
tion, prolonged survival times of DBA, mice 
inoculated i.p. with L1210 cells. Ulbrich et al. 
(1992) studied the in vivo release of targeted and 
non-targeted adriamycin conjugates from in- 
traperitoneally implanted, biodegradable hydro- 
gels. A disadvantage which these systems have in 
common is that laparotomy is needed to implant 
the device. 
Injectable formulations based on soluble poly- 
mers, synthesized for selective retention within 
the compartment, can be administered without 
surgery. Their application relies on physical size 
to regulate their drainage into the systemic circu- 
lation. Physical size (i.e., molecular mass) of solu- 
ble materials, however, is unable to mediate se- 
lective retention, materials up to 778 kDa show- 
ing uninhibited lymphatic transfer into the blood- 
stream (Seymour et al., 1987). 
One possible solution is the use of injectable 
formulations of particles, large enough to be se- 
lectively retained in the compartment but small 
enough to be injected without laparotomy. Albu- 
min-heparin conjugate microspheres (AHCMS) 
loaded with adriamycin (ADR) appear to be ideal 
for this purpose because they can be synthesized 
in any appropriate size (Cremers et al., 1990, 
1993a; Kwon et al., 1991) and they are known to 
release the drug in vitro by an ion exchange 
mechanism within a few hours after injection. 
The literature suggests that particles up to a 
diameter of 5 pm are transferred relatively easily 
out of the compartment, with reports of some 
transfer of materials up to 22.5 pm (Allen, 1956). 
Previously, Miyazaki et al. (1986) reported re- 
duced toxicity and increased antitumour activity 
of ADR formulated in relatively small fibrinogen 
microspheres (1.7 &- 0.7 pm> in an Ehrlich ascites 
carcinoma-bearing mouse model. In this paper 
the evaluation of ADR-AHCMS with a mean 
particle size of 23 pm as i.p. targeting devices 
against i.p. localized tumours is described. 
The i.p. biocompatibility of empty and drug- 
loaded particles was tested in a slightly modified 
version of the intraperitoneal biocompatibility test 
described by Pizzoferrato et al. (1987). Antitu- 
mour efficacy was determined in two different 
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animal models. The first tumour model system 
used, intraperitoneal L1210 leukaemia, is long 
established and routinely employed for the 
screening of novel anticancer agents (Duncan et 
al., 1988) and polymeric drug delivery implants 
(Heller et al., 1991). In the second study, a single 
intraperitoneal tumour model in the rat was used 
(Los et al., 1990). The tumour used, CC531, is a 
carcinoma originating in the colon of a rat ex- 
posed to methylazoxymethanol (Zedeck and 
Sternberg, 1974). 
2. Materials and methods 
2.1. Materials 
Albumin-heparin conjugate (AHC) containing 
10.9% w/w of heparin was synthesized and puri- 
fied according to procedures developed by Hen- 
nink et al. (1983). Highly refined olive oil was 
obtained from Sigma Chemical Co., St Louis, 
U.S.A. Glutaraldehyde (25% aqueous solution), 
obtained from Merck, Darmstadt, Germany, was 
purified by distillation and adjusted to 2.5% w/v 
aqueous solutions prior to use (Gillett and Gull, 
1972). Adriamycin was a kind gift from Farmitalia 
Carlo Erba, Milan, Italy. All other reagents were 
obtained, in the highest possible grade, from 
Merck, Darmstadt, Germany. 
2.2. Microsphere preparation and drug loading 
AHCMS were prepared as described before 
(Cremers et al., 1990, 1993a). Briefly, to 125 ml of 
prestirred (850 rpm) olive oil, 0.6 ml of a conju- 
gate solution in phosphate-buffered saline (100 
mg/0.6 ml PBS) was added. After emulsification 
for 15 min, 0.15 ml of glutaraldehyde solution was 
added. The emulsion was stirred at 850 rpm for 1 
h. 50 ml of acetone was then added and the 
emulsion was stirred for a further 10 min. The 
microspheres were isolated by centrifugation for 
15 min at 2700 rpm, followed by decanting of the 
supernatant. The microspheres were then washed 
several times with acetone. After collection, the 
microspheres were washed with distilled water 
and phosphate-buffered saline to remove un- 
bound material. Subsequently the AHCMS were 
dehydrated with ethanol and sieved, giving a dry 
size of lo-25 pm. 
Adriamycin loaded AHCMS (ADR-AHCMS) 
were prepared by 24 h incubation of 10 mg of 
AHCMS in 1 ml of adriamycin solution in dis- 
tilled water (5 mg/ml) and subsequent washing 
with water and acetone. Payloads were calculated 
from the ADR depletion in the loading solution 
and the ADR recovery in the washing steps 
(Cremers et al., 1993b). 
2.3. Biocompa tibility test 
ADR-AHCMS (44.93 mg) were resuspended 
in 1 ml of ethanol by sonication. To the suspen- 
sion, 51.6 ml of 5% w/v glucose solution was 
added. After 2 h of rotation at 4°C in the dark, 
the microspheres were centrifuged and the super- 
natant was decanted. Fresh glucose solution was 
added. Three suspensions were prepared: 1.5, 
0.75 and 0.375 mg/ml. Empty AHCMS were 
resuspended in 5% glucose solution and diluted 
to concentrations of 1.0, 0.5 and 0.25 mg/ml. The 
suspensions were stored overnight at 4°C until 
use. 
Male Balb/c mice (body weight approx. 40 g) 
were obtained from the Central Animal Labora- 
tory, University of Groningen, The Netherlands. 
Seven groups of mice were injected with approx. 
1 ml of a microsphere suspension as depicted in 
Table 1. One more group of mice served as a 
control and received only the 5% w/v glucose 
Table 1 
Experimental set-up of the intraperitoneal biocompatibility 
test 
Code No. of 
mice 
Material Dose 
(mg) 
C 
Ml 
M2 
M3 
AM1 
AM2 
AM3 
15 
9 
9 
15 
15 
15 
15 
control _ l-2-3-5-7 
AHCMS 0.25 l-3-7 
AHCMS 0.5 B l-3-7 
AHCMS 1.0 l-2-3-5-7 
ADR-AHCMS 0.375 l-2-3-5-7 
ADR-AHCMS 0.75 a l-2-3-5-7 
ADR-AHCMS 1.5 l-2-3-5-7 
(day) 
a This dose was calculated based on an adriamycin dose of 5 
mg/kg, which is the therapeutic dose used in the tumour 
model studies described below. 
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solution. At different time intervals (Table 1) 
three mice of each group were killed and a peri- 
toneal wash was carried out. The particles and 
cells in the peritoneal exudate were counted us- 
ing a Coulter counter. Then the exudate of the 
three mice was pooled and the particles and cells 
were identified using light microscopy on sections 
cut after embedding in Technovit 7100@ (Kulzer, 
Wehrheim, Germany). Five different groups were 
distinguished at identification: neutrophils, 
macrophages, lymphocytes, basophils/eosinophils 
and a group containing cells that could not be 
identified, microspheres, debris and dead cells 
which was categorized as ‘other’. Their percent- 
age in the LM sections was determined after 
classification of 200 cells per section. 
2.4. In vivo anti-tumour efficacy, L1210 mouse 
model 
Male DBA, mice (7-8 weeks old, 23-26 g 
each) were purchased from Bantin & Kingman 
Ltd, Hull, U.K. They were administered L1210 
cells (105) intraperitoneally, under light inhala- 
tional anaesthetic (Fluothane) on day 0. 
The mice were treated i.p. on days 1, 2 and 3, 
also under Fluothane anaesthetic, between 14:00 
and 15:00 to minimize circadian variations. Con- 
trol animals received 0.1 ml injections of 5% w/v 
glucose solution. Animals receiving free ADR 
were administered either 5 or 10 mg/kg daily in 
glucose solution (0.1-0.2 ml). ADR-AHCMS was 
formulated as described above and administered 
i.p. at a dose of either 5 or 10 mg/kg ADR on 
each day. 
Mice were monitored closely and weighed 
daily. Any animal losing 20% of body weight was 
killed immediately. Similarly, animals showing ei- 
ther obvious discomfort or extensive tumour bur- 
den (usually reflected as a weight greater than 34 
g) were also killed at once. Survival was moni- 
tored up to 100 days postadministration. 
2.5. In vivo anti-tumour efficacy, CC531 rat model 
Male Wag/Rij rats, 8-12 weeks old and 
weighing 220-260 g at the time of the experi- 
ments, were bred at the animal department of 
The Netherlands Cancer Institute (Amsterdam, 
The Netherlands) under specific pathogen-free 
(SPF) conditions. The animals were kept on a 12 
h light/l2 h dark cycle and fed standard rat chow 
and plain tap water ad libitum. Rats were anaes- 
thetized with ether. After preparation for opera- 
tion, a 1 cm incision was made into the median 
ventral abdominal wall, at about the transition of 
the upper and lower quadrants. A small part of 
the small intestines was exposed and a tumour 
disc, with a diameter of 3 mm and a thickness of 
1.5 mm, was implanted by a haemoclip fixation 
on the distal part of the mesentery. The tumour 
disc was obtained from the viable parts of subcu- 
taneous CC531 tumours. The bowel was reposi- 
tioned and the abdomen closed by three to four 
interrupted sutures. For assessing i.p. tumour 
growth a new laparotomy was performed at each 
measurement made at 2 weekly intervals. The 
size of the tumour was assessed by measuring 
three diameters of the tumour using Vernier 
calipers. The geometric mean of the three values 
was then calculated and used as the size estimate, 
since this gives a better estimate of volume for 
non-spheroid tumours. The overall mean and SD 
were then calculated from the geometric means 
of tumours in each group at set time points. 
The tumour was implanted at day - 11. Ani- 
mals were treated in three groups of four rats 
each and one group of five animals (control) on 
day 0. All animals were administered 20 ml of 
solution or suspension. The control animals re- 
ceived 5% w/v glucose solution. The first treat- 
ment group was administered free ADR at a dose 
of 5 mg/kg. The second and third group were 
treated with ADR-AHCMS at doses of 5 and 10 
mg/kg of ADR, respectively. Tumour growth was 
determined at days -5, 7, 21, 35 and 49. 
3. Results and discussion 
AHCMS and ADR-AHCMS were prepared 
according to standard procedures as previously 
described by Cremers et al. 0993a,b). ADR re- 
lease from ADR-AHCMS upon suspension of the 
microspheres in aqueous medium was as de- 
scribed previously. The amount of drug released 
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control AHCMS AHCMS AHCMS ADR-MS ADR-MS ADR-MS 
C Ml M2 M3 AM1 AM2 AM3 
treatment group 
Fig. 1. Number of particles measured in peritoneal exudate, 1 day after i.p. administration of microspheres in Balb/c mice. 
(H 1 Neutrophils; (Ka 1 lymphocytes; ( q 1 macrophages; (0) basophils/ eosinophils; ( N ) other (codes explained in Table 1). 
varied between 2 and 30% w/w of the incorpo- 
rated drug depending on the batch of ADR- 
AHCMS used. This was taken into account in the 
preparation of the injections. 
3.1. Intraperitoneal biocompatibility test 
The microsphere concentration of the suspen- 
sions used in the i.p. biocompatibility experi- 
ments is based on a therapeutically applied ADR 
dose of 5 mg/kg. The mice seemed to be unaf- 
fected by the i.p. administration of the micro- 
sphere suspensions, except for those receiving the 
highest ADR-AHCMS dose (10 mg/kg, AM3). 
These mice seemed to be less lively on the first 
day after administration. The peritoneum of these 
mice showed some milky spots, indicating necro- 
sis at sites where the microspheres adhered to the 
peritoneum. It was also noticed that up to day 3 
after administration of ADR-AHCMS, the super- 
natant of the peritoneal exudate was coloured 
red. This indicates the presence of free adri- 
amycin or metabolites. At day 7 only the pellet 
obtained after centrifugation of the peritoneal 
exudate was coloured. 
Fig. 1 shows the number and identification of 
particles and cells measured in the i.p. exudates 
on day 1. From Fig. 1 it can be seen that there is 
a dose-dependent inflammatory response in the 
case of empty AHCMS as well as ADR-AHCMS: 
In both cases the infiltration of cells increases 
with increasing dose. This can also be observed 
from Fig. 2 which shows the neutrophils mea- 
sured after administration of particles, stand- 
ardized with respect to control animals. It can be 
seen that the dose dependence of the response to 
the ADR-AHCMS lasts for a few days. 
25 
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Fig. 2. Number of neutrophils measured after i.p. administra- 
tion of microspheres in Balb/c mice, relative to controls. (H) 
Ml; (0) M2; (A) M3; (0) AMl; (0) AM2; (A) AM3 (codes 
explained in Table 1). 
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25, I 
0 1 2 3 4 5 6 7 
time [days] 
Fig. 3. Number of cells and particles after i.p. administration 
of 0.75 mg ADR-MS (AM21 in male Balb/c mice, relative to 
controls. ( n ) Neutrophils; (0) lymphocytes; (0) macrophages; 
CO) basophils/eosinophils; (A) other. 
An acute inflammatory response is character- 
ized by the infiltration of primarily neutrophils 
and to a lesser extent, of macrophages. The in- 
crease in cells and particles as shown in Fig. 3, 
with a predominant increase in the number of 
neutrophils, is typical of an acute inflammatory 
response. Fig. 3 shows the amounts of cells and 
particles after i.p. administration of ADR- 
AHCMS at the ‘normal dose’, relative to the 
controls. At day 1 the neutrophil level is in- 
creased significantly. The number of lymphocytes 
and basophils/ eosinophils, which is an indication 
for immunological and allergic reactions, is barely 
increased. 
Fig. 3 also shows a significant increase in 
unidentifiable cells and debris (categorized as 
‘other’), mainly at day 2. This phenomenon only 
occurred with ADR-AHCMS at normal and at 
double dose (AM2 and AM3, see also Fig. 1). 
This increase is most likely due to the cytotoxicity 
of the ADR, causing more cell death at higher 
doses. At day 2, the peritoneal infiltration was 
still characterized by an increased number of 
neutrophils, .although the response was already 
strongly reduced. At day 3 the response was 
further decreased and could only be observed 
with the highest doses of microspheres and at 
days 5 and 7 no significant responses were ob- 
served (data not shown). Viewed overall, these 
Table 2 
Survival of mice inoculated with L1210 cells, after treatment 
with ADR or ADR-AHCMS 
Treatment a Median Alive at 
T/C b day 100 
(%I 
Signifi- 
cance ’ 
Free ADR, 5 mg/kg 155 
Free ADR, 10 mg/kg 45 
ADR-AHCMS, 5 mg/kg 236 
ADR-AHCMS, 10 mg/kg 209 
l/5 (20%) - 
o/5 (0%) + 
2/5 (40%) + 
o/5 (0%) + 
a Single administration dose; animals were adminstered three 
doses. 
b T/C values calculated with control median = 11 days; mean 
= 13 days. 
’ Differences, as compared with controls, are significant at 
p < 0.05 levels as determined by log-rank test. 
acute inflammatory responses are quantitatively 
very slight and they suggest hat the AI-EMS and 
ADR-AHCMS are well tolerated after i.p. ad- 
ministration to mice. 
3.2. L1210 tumour-bearing mouse model 
The results of the anti-tumour efficacy investi- 
gation of ADR-AHCMS in L1210 i.p. inoculated 
mice are listed in Table 2 and are shown in Fig. 4. 
Median survival times are shown in Table 2, 
whereas the graph shows the survival of the mice. 
The controls (sham-treated animals) showed rapid 
@ T 80 
P ._ 
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2 
I 40 
E 
‘E m 20 
0 
0 7 14 21 28 35 42 100 
time [days] 
Fig. 4. Survival time of DBA2 mice inoculated i.p. with L1210 
tumour. (0) Control; (0) ADR, 3 x5 mg/kg; ( n ) ADR, 
3 X 10 mg/kg; (A) ADR-AHCMS, 3 x 5 mg/kg; (A ) ADR- 
AHCMS, 3 x 10 mg/kg. 
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weight gain, beginning on day 8; all animals died 
from tumour burden. Animals treated with free 
ADR (3 x 10 mg/kg) showed weight loss indica- 
tive of severe toxicity and were killed on day 5. 
Those receiving the optimum therapeutic dose of 
free ADR (3 x 5 mg/kg) died from a mixture of 
tumour burden and toxicity with one animal still 
alive at day 100 (Fig. 4). The increase in survival 
times with respect to controls was not significant 
at a p < 0.05 level as determined using a log-rank 
test (Table 2). 
Animals receiving ADR-AHCMS were treated 
with three doses of either 5 or 10 mg/kg. Those 
receiving 10 mg/kg demonstrated a substantial 
decrease in toxicity compared with the same dose 
of free drug. All animals showed some signs of 
toxicity like peritoneal oedema and weight loss 
although none met the criteria for early killing. 
The animals showed some recovery from these 
effects which were worst on about day 5, although 
all eventually succumbed to treatment-related 
deaths. On autopsy there were no signs of any 
tumour burden in these mice. Animals treated 
with 3 x 5 mg/kg of ADR as ADR-AHCMS 
showed only slight toxicity effects, with just a 
small initial fall in body weight. They appeared 
outwardly healthy for the first 20-25 days of the 
experiment. On about day 18 some animals began 
to show a regular increase in weight, and tumours 
were manifest in three animals on day 24. Tu- 
mours then grew rapidly. Two animals were free 
of tumour and still alive at day 100. Treatment 
with ADR-AHCMS at both doses improved the 
survival of mice significantly, as compared with 
controls (Fig. 4 and Table 2). Treatment with 
empty AHCMS did not significantly increase the 
survival time of L1210 inoculated mice as com- 
pared to untreated controls (data not shown). 
3.3. CC531 tumour-bearing rat model 
CC531 tumour growth curves are shown in Fig. 
5. The plots show that i.p. treatment with 5 
mg/kg free ADR reduced the tumour growth 
significantly. Treatment with 5 mg/kg ADR- 
AHCMS reduced tumour growth even more. At 
day 35, two out of three surviving animals were 
free of tumour. All animals treated with the 
-14 -7 0 7 14 21 28 35 42 49 
time [days] 
Fig. 5. Tumour growth delay of mesenteric CC531 tumours, 
implanted at day - 11 in Wag/Rij rats, following i.p. treat- 
ment at day 0. Treatment: (0) ADR, 5 mg/kg; (0) ADR- 
AHCMS, 5 mg/kg; (m) ADR-AHCMS, 10 mg/kg; (A) con- 
trol. Each point represents mean; error bars indicate SD. 
highest dose of ADR-AHCMS (10 mg/kg) had 
died from toxicity, evident as peritoneal oedema, 
by day 35. In this group tumour growth over the 
first 20 days was not significantly different from 
the controls. 
At day 21 one animal in the ADR-treated 
group and one animal in the ADR-AHCMS (10 
mg/kg) group had died. Most other animals in 
these groups showed severe ascites. This was also 
noticed in the ADR-AHCMS (5 mg/kg) group at 
later stages. At day 21 only one animal in this 
group suffered from ascites and at day 35 one 
animal had died and the remaining animals all 
showed signs of ascites. 
The cause of the ascites is still not completely 
clear. In a control experiment animals were 
treated with empty AHCMS. This treatment did 
not have any effect on the tumour growth. None 
of the animals showed any signs of ascites. This 
implies that the ascites is ADR-related. Los et al. 
(1990) treated i.p. CC531 tumour-bearing Wag/ 
Rij rats intraperitoneally with ADR at a dose of 4 
mg/kg. At this dose, tumour growth was initially 
delayed. At day 21, however, tumours started 
growing at a rate comparable to that of controls. 
The authors did not report any adverse effects 
due to ADR administration. This suggests that 
the applied dose (4 mg/kg) was safe in terms of 
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toxicity, but less effective in tumour growth con- 
trol than the treatment (5 mg/kg) applied here. 
0201s et al. (1982) reported that the dose-limiting 
factor in intraperitoneal ADR in patients was 
chemical peritonitis. Treatment at concentrations 
greater than 36 PM induced sterile ascites and 
peritoneal adhesions. Hence, intraperitoneal 
ADR toxicity is dose dependent as well as species 
dependent. In the case of rats, ascites was already 
evident at the 5 mg/kg dose, in the case of both 
free drug and ADR-AHCMS. In the L1210 mouse 
model, acute toxicity was observed with free ADR 
only at a dose of 3 x 10 mg/kg. Long-term ef- 
fects indicated by ascites were only observed after 
3 x 10 mg/kg ADR-AHCMS treatment, not at 
the therapeutically applied dose of 3 x 5 mg/kg 
ADR-AHCMS. 
4. Conclusions 
The intraperitoneal biocompatibility test in 
male Balb/c mice showed that empty AHCMS 
provoked only a mild dose-dependent inflamma- 
tory response, indicated by the infiltration of pre- 
dominantly neutrophils. Incorporation of ADR 
into the AHCMS did not significantly enhance 
this response. At a drug dose of 10 mg/kg, how- 
ever, a greater extent of cell death was initially 
observed, probably due to the presence of high 
amounts of ADR. 
The L1210 tumour-bearing mouse model and 
the CC531 tumour-bearing rat model both showed 
an increase in antitumour efficacy when the drug 
was formulated in AHCMS. The administration 
of ADR-AHCMS instead of ADR reduced the 
acute toxicity in both models. Higher drug doses 
were initially tolerated. At a dose of 3 X 10 
mg/kg, however, mice developed ascites. In rats 
this was observed at lower doses (5 mg/kg). 
It is encouraging that formulation of ADR in 
AHCMS increases the antitumour activity of 
ADR against wo different types of tumour model. 
There appears to be a balance between reduction 
of the acute toxicity and induction of chemical 
peritonites and ascites as a long-term effect. This 
calls for more research directed towards the im- 
provement of dose and dosage schedules of mi- 
crosphere drug delivery systems in i.p. 
chemotherapy. 
It might be expected that regional therapy with 
a particulate formulation would show particularly 
good activity against tumour models which tend 
to grow in the omentum (eg. L1210), since this is 
also known to be the main site of accumulation of 
particles injected intraperitoneally (Seymour et 
al., 1991). However, the good activity demon- 
strated against solid CC531 tumours also impli- 
cates a component of sustained drug release. 
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